Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diwakar Davar

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Drug Design, Development and Therapy|August 30, 2018
MEK inhibitors for the treatment of NRAS mutant melanomaSaro Sarkisian, Diwakar Davar
Journal for Immunotherapy of Cancer|January 29, 2026
Advancing ICOS agonism in solid tumors: lessons from INDUCE-1Parham Habibzadeh, Diwakar Davar
Oncotarget|June 19, 2023
Targeting GITR in cancer immunotherapy - there is no perfect knowledgeDiwakar Davar, Roberta Zappasodi
Cancer|February 10, 2026
Revisiting the impact of common medications on immune checkpoint inhibitor efficacyParham Habibzadeh, Diwakar Davar
Chinese Clinical Oncology|July 12, 2022
The role of systemic therapy in melanoma brain metastases: a narrative reviewKainat Saleem, Diwakar Davar
Cancer Immunology Research|February 19, 2024
Immunomodulatory Effects of RANK/RANKL Blockade in Patients with CancerElham Nasrollahi, Diwakar Davar
Targeted Oncology|January 6, 2018
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical ExperiencesDiwakar Davar, Nathan Bahary
Cancer Immunology Research|March 14, 2025
There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint Blockade in Urothelial CarcinomaArivarasan Karunamurthy, Diwakar Davar
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition ReduxDiwakar Davar, John M Kirkwood
Cancer Treatment and Research|November 26, 2015
Adjuvant Therapy of MelanomaDiwakar Davar, John M Kirkwood
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Drug Design, Development and Therapy|August 30, 2018
MEK inhibitors for the treatment of NRAS mutant melanomaSaro Sarkisian, Diwakar Davar
Journal for Immunotherapy of Cancer|January 29, 2026
Advancing ICOS agonism in solid tumors: lessons from INDUCE-1Parham Habibzadeh, Diwakar Davar
Oncotarget|June 19, 2023
Targeting GITR in cancer immunotherapy - there is no perfect knowledgeDiwakar Davar, Roberta Zappasodi
Cancer|February 10, 2026
Revisiting the impact of common medications on immune checkpoint inhibitor efficacyParham Habibzadeh, Diwakar Davar
Chinese Clinical Oncology|July 12, 2022
The role of systemic therapy in melanoma brain metastases: a narrative reviewKainat Saleem, Diwakar Davar
Cancer Immunology Research|February 19, 2024
Immunomodulatory Effects of RANK/RANKL Blockade in Patients with CancerElham Nasrollahi, Diwakar Davar
Targeted Oncology|January 6, 2018
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical ExperiencesDiwakar Davar, Nathan Bahary
Cancer Immunology Research|March 14, 2025
There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint Blockade in Urothelial CarcinomaArivarasan Karunamurthy, Diwakar Davar
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition ReduxDiwakar Davar, John M Kirkwood
Cancer Treatment and Research|November 26, 2015
Adjuvant Therapy of MelanomaDiwakar Davar, John M Kirkwood
Pageof 10